GBR12909 possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but cardiac ion channel effects limit its clinical utility

Pharmacology

Volumn 79, Issue 4, 2007, Pages 250-258

  Goldsmith, Paul ^a,e   Golder, Zoe ^a   Hunt, Julia ^a   Berghmans, Stephane ^a   Jones, Derek ^a   Stables, James P ^b   Murphree, Lauren ^b,c   Howden, Diane ^b   Newton, Paul E ^d   Richards, Frances M ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c GENERAL DYNAMICS   (United States)

^d MPI RESEARCH   (United States)

^e VASTox plc   (United Kingdom)

Author keywords

Anticonvulsant; Arrhythmia; Dopamine reuptake inhibitor; GBR12909; Therapeutic window; Zebrafish

Indexed keywords

AMIODARONE; BICUCULLINE; CARBAMAZEPINE; CISAPRIDE; DIPHENHYDRAMINE; ION CHANNEL; PENTETRAZOLE; PICROTOXIN; PIMOZIDE; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CARDIAC CHANNELOPATHY; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; ELECTRIC SHOCK; EPILEPSY; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RAT; RODENT; ZEBRA FISH;

ANIMALS; ANTICONVULSANTS; ARRHYTHMIAS, CARDIAC; DOGS; DOPAMINE UPTAKE INHIBITORS; ELECTROCARDIOGRAPHY; EPILEPSY; ETHER-A-GO-GO POTASSIUM CHANNELS; MALE; MICE; MYOCARDIUM; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; ZEBRAFISH;

EID: 34249773996     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102061     Document Type: Article

References (23)

1. Andersen PH: The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 1989; 166: 493-504.
2. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y: Anticonvulsant action of GBR-12909 and citalopram against acute experimentally induced limbic seizures. Neuropharmacology 2004; 47: 1053-1061.
3. Baraban SC, Taylor MR, Castro PA, Baier H: Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 2005; 131: 759-768.
4. Goldsmith P: Zebrafish as a pharmacological tool: the how, why and when. Curr Opin Pharmacol 2004; 4: 504-512.
5. Langheinrich U: Zebrafish: a new model on the pharmaceutical catwalk. Bioessays 2003; 25: 904-912.
6. Parng C, Roy NM, Ton C, Lin Y, McGrath P: Neurotoxicity assessment using zebrafish. J Pharmacol Toxicol Methods 2006, Epub ahead of print.
7. Parng C, Seng WL, Semino C, McGrath P: Zebrafish: a preclinical model for drug screening. Assay Drug Dev Technol 2002; 1: 41-48.
8. Sogaard U, Michalow J, Butler B, Lund Laursen A, Ingersen SH, Skrumsager BK, Rafaelsen OJ: A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. Int Clin Psychopharmacol 1990; 5: 237-251.
9. Langheinrich U, Vacun G, Wagner T: Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol Appl Pharmacol 2003; 193: 370-382.
10. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA: Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 2003; 107: 1355-1358.
11. Westerfield M, Doerry E, Kirkpatrick AE, Driever W, Douglas SA: An on-line database for zebrafish development and genetics research. Semin Cell Dev Biol 1997; 8: 477-488.
12. Swinyard EA, Clark LD, Miyahara JT, Wolf HH: Studies on the mechanism of amphetamine toxicity in aggregated mice. J Pharmacol Exp Ther 1961; 132: 97-102.
13. Lothman EW, Williamson JM: Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: a rapidly developing, transient kindling and a slowly developing, enduring kindling. Brain Res 1994; 649: 71-84.
14. Racine RJ: Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32: 281-294.
15. Woodbury DM: Experimental models of status epilepticus and mechanisms of drug action. Adv Neurol 1983; 34: 149-160.
16. Preti A: Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs 2000; 1: 241-251.
17. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM: HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005; 52: 136-145.
18. Ogren SO, Pakh B: Effects of dopamine d1 and d2 receptor agonists and antagonists on seizures induced by chemoconvulsants in mice. Pharmacol Toxicol 1993; 72: 213-220.
19. George B, Kulkarni SK: Dopaminergic modulation of lithium/pilocarpine- induced status epilepticus in rats. Methods Find Exp Clin Pharmacol 1997; 19: 481-488.
20. Yokoyama H, Onodera K, Iinuma K: MK-801 and dopaminergic system in electrically-induced convulsions in mice. Yakubutsu Seishin Kodo 1993; 13: 309-313.
21. Heikkila RE, Manzino L: Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol 1984; 103: 241-248.
22. Fleming A, Sato M, Goldsmith P: High-throughput in vivo screening for bone anabolic compounds with zebrafish. J Biomol Screen 2005; 10: 823-831.
23. Zon LI, Peterson RT: In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005; 4: 35-44.